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Abstract 
 
Anxiety affects approximately 1/3 of the US population and presents in many different 
forms, ranging from social to panic disorders. It also presents with high comorbidity for other 
mental disorders. One treatment is Selective Serotonin Reuptake Inhibitors (SSRIs) which allow 
for increased activation of serotonin (5-HT) receptors. SSRIs come with an extensive list of side 
effects, which can fail to maintain quality of life. Cannabidiol (CBD) is a cannabis derived 
compound which has been shown to decrease anxiety by activation of multiple subtype 5-HT 
amine receptors. CBD has few side effects, is not psychoactive, and exhibits anti-psychotic 
properties. The current understanding of CBD's mechanisms is limited specifically in 
invertebrates, where to date limited published research involves behavior and cannabinoids. 
Decapod crustaceans, such as crayfish, have emerged as a novel approach to studying drugs of 
abuse. Within the neural structures of the crayfish tails are 5-HT receptors that control tail-flips, 
a withdraw reflex when placed into a fight. Serotonin has also been linked to aggression and 
decision making for engaging in fights with other crayfish. Additionally, evidence currently 
suggests CB1 receptors are present at neuromuscular junctions (NMJ) and may have an impact 
on motility. For this thesis, crayfish were administered either CBD, 5-HT, or a vehicle control. 
Analysis of motility by percent of time moving or rest, amount of food consumed, and 
aggression in paired fights were conducted. No statistical significance was found for CBD 
influencing motility and hunger. However, the duration of fights significantly increased when 
injected with CBD and when paired with 5-HT injected crayfish. This evidence supports the 
main hypothesis that CBD increases serotonin receptor activity in crayfish as seen with SSRIs, 
thus could be of use in treating anxiety.   
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Hypothesis 
 The primary goal of this study was to provide evidence that CBD increases 5-HT receptor 
activity in crayfish tail neural tissue resulting in decreased tail-flip behavior. This same escape 
reflex has been shown to be decreased with use of SSRIs. Additionally, there are serotonin 
receptors lining the digestive system in crayfish that could be influenced by CBD. Finally, 
cannabinoid receptors have been found in the NMJ of crayfish thus suggesting that CBD may 
increase or decrease the motility of crayfish. The ultimate question at hand was if CBD is an 
adequate candidate for replacing SSRIs when gauged by serotonin activation in crayfish. Hunger 
and motility behaviors could also be changed by CBD and were thus explored.   
 
Specific Aims 
 
The most prevalent mental disorder in the US is anxiety, affecting 33.7% of the 
population at one point in their life. Generalized Anxiety Disorders (GAD), Social Anxiety 
Disorders (SAD), agoraphobias, panic disorders, and specific phobias make up what is 
generalized into anxiety. One concerning component of anxiety is the high comorbidity for other 
mental disorders. One method of treatment is Selective Serotonin Reuptake Inhibitors (SSRIs) 
which allow for increased activation of serotonin (5-HT) receptors. However, SSRIs come with 
an extensive list of side effects, some of which fail to maintain quality of life. Cannabidiol 
(CBD) is a cannabis derived compound which has been shown to decrease anxiety by activation 
of multiple subtype 5-HT amine receptors. Unlike SSRIs, CBD has few side effects. 
Additionally, it is not psychoactive and even has anti-psychotic properties. CB1 receptors can 
have bound CBD where it acts as an allosteric inhibitor of anandamide resulting in decreased 
drive for food. The current understanding of CBD’s mechanisms is limited specifically in 
invertebrates where to date no published articles involve behavior and cannabinoids. Decapod 
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crustaceans, specifically crayfish, have emerged as a novel approach to studying drugs of abuse. 
Crayfish tails contain 5-HT receptors that control tail-flips, a withdrawal reflex to rapidly retreat. 
One specific serotonin linked behavior is aggression and decision making for engaging in fights 
with other crayfish. Additionally, evidence currently suggests CB1 receptors are present at 
neuromuscular junctions (NMJ) and may have an impact on motility. Preliminary studies were 
conducted to evaluate any change CBD has on the NMJ. 
 
Aim 1: Observe and measure fights of equal sized crayfish via time spent engaged in 
aggressive behavior and fight duration. Crayfish administered with CBD and 5-HT or agonist 
will be paired by weight and placed into fights. The correlation between time and behavior will 
indicate how CBD and SSRIs compare within simple neural structures.  
Aim 2: Observe and measure amount of food consumed. CBD and 5-HT or agonist will be 
administered. The quantitative consumption will indicate how CBD and SSRI compare on 
hunger.   
Aim 3: Examine motility by time spent resting verses moving. CBD and saline control 
injections will be completed in crayfish. The resulting ability to move will be examined to 
determine if CBD has an influence on the neuromuscular junction.  
 
CBD has been shown to influence the same receptors as serotonin that produce anxiety. Over a 
third of the population will experience an anxiety disorder. The current SSRIs used to return 
functionality to impacted individual leaves them exposed to equally unpleasant side effects. A 
new treatment may be found through CBD which offers potentially comparable relief without the 
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tradeoff of current medications. Treatment with CBD in crayfish should produce similar results 
of those injected with serotonin.    
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Introduction and Background 
 
Anxiety Economics and Prevalence 
 
 The economic and epidemiological survey of mental disorder can best be described as 
common and costly. Mental illnesses, including anxiety are ranked in the top five global 
exorbitant conditions. The out of pocket costs for treatment were found to be 23.1% in 1996, and 
25.0% in 2006. In addition, mental disorders saw a rise in total costs from $35.2 billion to $57.5 
billion between 1996 to 2006. This correlated with the total number of cases increasing from 
19.3 million to 36.2 million in the same time frame(1). Estimates in the year 2010 indicate that 
the cost is now around US $2.5 trillion and will increase to $6.0 trillion by 2030. In addition to 
direct costs of treatment for an illness one must consider the indirect expenses of an illness such 
as the Disability-Adjusted Life Year (DALY). Mental illnesses have a larger impact on the 
DALY then other chronic conditions such as diabetes (2,3). Despite having high cost and 
prevalence associated with mental disorders, the general public places higher budgetary priority 
on somatic illness such as cancer and diabetes (4). Multiple economic and personal burdens are 
associated with mental disorders and there is a need for more awareness (5). The most prevalent 
mental disorder in the US was found to be anxiety of any type ranging from 18.0% (6) to 38.0% 
(7). This includes general anxiety disorders (GAD), social or separation anxiety disorders (SAD), 
agoraphobias, specific phobias, social phobias, panic disorders, and post-traumatic stress 
disorders (PTSD). Anxiety was found to be comorbid with other mental illnesses like depression 
and bipolar disorders as well as physical disabilities such as asthma or diabetes (3,8).  
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Anxiety Pathology 
 
The pathological cause of mental illness is a complex network of disruptions in normal 
brain activity. One such area of interest for depression and anxiety is the group of serotonin 
amine receptor family along with norepinephrine (NE) turnover (Reviewed by Ressler and 
Nemeroff 2000). 5-HT receptors are found throughout the central nervous system such as the 
pathways of the basal ganglia, hippocampus, hypothalamus and spinal cord through the dorsal 
raphe. Serotonin receptors include 12 different subtypes, such as the 5-HT1A, 5-HT1D, 5-HT2A, 5-
HT2C, 5-HT3, and 5-HT4 families (10–12). For this study, the action of the 5-HT1A receptor as 
related to anxiety was investigated. 5-HT1A abnormalities have been well documented for their 
presence in patients with depression and anxiety. One example is the analysis of suicide victim 
who experienced depression. The dysregulation of 5-HT1A in the victims indicated a direct 
correlation to amine-based receptor malfunctions and decreased receptor prevalence. In addition, 
positron emission tomography (PET) of comorbid patients for panic disorders and depression 
revealed significant alterations in the 5-HT1A receptor prevalence compared to controls (13). A 
similar PET scan study using males with SAD indicated a deceased binding potential for the 5-
HT1A receptors (14). One explanation for the dysregulation could genetic predisposition. Genetic 
examination concluded that up regulation of auto receptors within the dorsal raphe from simple 
nucleotide polymorphism (SNP) could result in the decreased firing rate (15,16). Evidence also 
suggests that 5-HT1A plays a key role in development of emotional behaviors. This was shown 
with fine tuning of the 5-HT1A heteroreceptors and auto receptors using knockout mice models 
(16–18). To summarize, PET scans, genetic predisposition, pharmacological studies and post 
mortem analysis all concluded that 5-HT1A has a crucial role in anxiety. This is postulated to be 
due to a decreased binding potential in the pathological state for anxiety and depression (19). But 
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the actual role of serotonin and 5-HT1A activation is still under debate. Serotonin dysregulation 
has also been linked to neurodegenerative disease like Parkinson’s where it presents with 
depression (11) and tremors (20). The current treatment for pathological 5-HT receptor 
abnormalities is with Selective Serotonin Reuptake Inhibitors (SSRIs). The current theory for 
SSRI treatment is that additional 5-HT is available for activating 5-HT1A. This results in a less 
pathological state for treatment of anxiety and depression disorders (21).  
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Anxiolytic Medication and Side Effects 
 
 One option for treatment of anxiety disorders is use of SSRI compounds, such as 
paroxetine, fluvoxamine, sertraline, fluoxetine, and escitalopram. SSRIs have been shown to be 
effective in both anxiety and depression and are often utilized when disease states presents 
individually or in comorbidity (22). Early studies on paroxetine, fluvoxamine, sertraline and 
fluoxetine and citalopram concluded the statistical significance in decreased social anxiety based 
on the Liebowitz Social Anxiety Scale (LSAS)(23), while later summaries of the studies show 
additional evidence that included escitalopram (24). The primary mode of action of SSRIs is to 
produce additional synaptic 5-HT, thus increasing the activation of the serotonin receptors (25). 
However, the hypothesized activation of various subtypes of receptors in the body could be the 
source of multiple side effects (10). These include alterations in sexual function leading to 
delayed ejaculation, decreased libido, and anorgasmia in up to 60% of patients. Gastrointestinal 
systems can include nausea, diarrhea, dry mouth, constipation, and anorexia. The central nervous 
system can be impacted to produce anxiety, insomnia, sedation, and nightmares. This can include 
extrapyramidal symptoms like akathisia (constant movement or motor restlessness). 
Approximately twenty five percent of patients on SSRIs have reported insomnia or somnolence. 
Additional adverse effects include bleeding by inhibition of platelet function resulting in bruising 
and epistaxis. Hyponatremia can occur but is rare. Serotonin syndrome can arise from 
hyperstimulation of the 5-HT receptors if SSRIs are used with monoamine oxidase inhibitors, 
pentazocine or L-tryptophan. This overstimulation leads to nausea, diarrhea, restlessness, 
extreme agitation, hyperreflexia, autonomic instability, myoclonus, hyperthermia, rigidity, 
delirium, seizures and status epilepticus. In extreme instances this can lead to cardiovascular 
collapse, coma and death. The withdrawal from use of SSRIs can lead to discontinuation 
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syndrome, characterized by dizziness, nausea, weakness, insomnia, anxiety, irritability and 
headache. These symptoms dissipated over time, usually a few weeks. Tapering off SSRIs before 
complete discontinuation helps alleviate withdrawal symptoms(26). The prevalence of these side 
effects is well documented. In one cohort study of 584 patients actively on SSRIs the top most 
side effects included sleepiness during the day (21%), dry mouth (22%), profuse sweating (20%), 
sexual dysfunction (19%), dizziness (12%). Sleepiness, restlessness, muscle spasm, twitching, 
nausea, constipation, and diarrhea were reported below at or below 10% of cases (27). An 
additional study conducted using a drug safety monitoring service utilized a Treatment 
Satisfaction Questionnaire for Medications (TSQM) to collect patient data for those on SSRIs of 
citalopram, escitalopram, fluoxetine, paroxetine, and sertraline. Of the approximate 700 patients 
surveyed, 38% indicated that they experienced one or more side effect, while 229 listed the 
adverse effect of sexual dysfunction, sleepiness, and weight gain as the most crucial. The 
symptoms were also ranked by how bothersome they presented which indicated that 7% found 
them extremely bothersome, 19% very bothersome, 40% somewhat bothersome, 29% little 
bothersome, and 5% not at all bothersome (28). One of the earlier studies on SSRI use for 75-
105 days examined 401 patients via phone interviews to conclude that 344 (86%) reported 
experience at a minimum one side effect, while 219 (55%) indicated that at least 1 or more of the 
side effects was bothersome. Sexual dysfunction and drowsiness tied at 17% for most common 
bothersome. Those who experienced a side effect in the first two weeks indicated that at the end 
of the study blurred vision (85%) and sexual dysfunction (83%) remained. These results show 
how the bothersome side effects are persistent after three months of treatment (29). One 
hypothesis for the range of side effects centers on SSRIs causing inhibition of dopamine 
neurotransmitter release either by direct interaction or by modulation of serotonin receptors for 
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dopamine. This was concluded by examination of clinical reports on side effect occurrences and 
instances where stimulation of dopamine releasing treatments counteracted SSRI side effects 
(30). Due to the high out-of-pocket cost of treatment, increased prevalence, and well documented 
side effect, alternative treatments for anxiety have been pursued. One such treatment with 
potential anxiolytic effect is cannabidiol (CBD), a phytocannabinoid derived the plant cannabis 
sativa (31).     
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CBD and Endocannabinoids 
 
 Cannabidiol or CBD has emerged as a novel compound for its various interaction with 
multiple receptors in the human body. These receptors include CB1, CB2, PPARγ, and 5-HT1. 
The correlated physiological response is weight loss, insulin sensitivity, reduced atherosclerosis, 
and anxiolysis respectively. Additionally, CBD has been found to lower high glucose levels and 
cell inflammation due to its antioxidant, anti-inflammatory properties (32), relief of Αβ-Induced 
neuroinflammation to promote hippocampal neurogenesis as related to Alzheimer’s disease (33), 
protective properties against myocardial ischemic reperfusion injuries (34), and treatment 
potential for acute and anticipatory nausea (35). Cannabinoids in medicine is not unheard as 
documentation indicates that cannabis was used in China over a thousand of years ago (36). The 
recent rediscovery of its benefits has led to a surge into marijuana medical research. Over the 
past thirty years extensive research has been done on cannabis receptors within the human body. 
This led to discovery of endogenous cannabinoids used in the human body that specifically act 
on the hunger drive mechanism (37). The safety limit for CBD was found through animal models 
and human trials to be safe at elevated levels beyond the useful range (38). CBD has long been 
known to counteract the effects of Δ9-THC, the active component of cannabis that produces the 
sensation of feeling high as well as paranoia and anxiety. This was shown in a study that used 
human subjects who consumed both compounds and were surveyed for anxiety and paranoia 
(39). Extending past this, CBD has been shown to be non-psychoactive and even display anti-
psychotic properties through both human trials and animal studies (40). Investigation into the 
antianxiety effects of CBD have been promising. The use SSRIs was compared against CBD to 
determine the potency of anxiolysis. Elevated plus-maze evaluations of anxiety with CBD in rats 
concluded with increased time spent on the open arms (41). Similarly, Vogel conflict tests with 
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rats came to the same conclusion that CBD had alleviated anxiety behavior as observed by 
increased punished licks (42). The use of CBD in humans produced a U-shaped curve for 
decreased anxiety similar to those found with SSRIs when subjects were placed into public 
speaking scenarios (43). In addition, a dampened emotional response was not seen with 
treatment of CBD. A study of 38 healthy individuals concluded that CBD did not numb 
emotional responses to negative social stimuli nor social rejection which indicates that behavior 
changes are not seen with use of CBD (44). The specific physiological reason that CBD has 
antianxiety properties has been thought to be from the effect on 5-HT receptors. This was 
demonstrated by administrations of CBD to the dorsolateral periaqueductal of rats followed by 
observations on elevated plus-maze and Vogel conflict test. Use of an antagonist to 5-HT1a 
stopped the effects from the CBD(45). Alternatively, the co-presence of 5-HT3a and CB1 in the 
interneurons of the hippocampus and dentate gyrus was found through situ hybridization 
histochemistry and could lead to avenues for research. Additional studies are required to further 
determine the extent that these receptors play on anxiety (46). To better understand the social and 
behavior effects of CBD examination in other biological systems could provide further insight. A 
recent approach to pharmacology has been to use invertebrates as models for physiology. Recent 
studies have shown evidence for CB1 receptors at the neuromuscular junction(NMJ) of crayfish 
from antibody-selective immunofluorescent staining microscopy (47) and pharmacological 
activation measured via excitatory post synaptic potentials electrical amplitude (48). In addition 
to the cannabinoid receptors, 5-HT receptors are also found within crayfish. The approach to 
using SSRIs within crayfish has been shown to dramatically change the outcome of their 
behaviors as serotonin receptors play a crucial role in aggression and social ranking.  
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Crayfish Physiological Model  
 
 Decapod crustaceans, specifically crayfish, have emerged as a novel physiological model 
for studying pharmacological properties. Some of the most dramatic example include studies 
involving drugs of abuse where the behavior changes were most notable. (49–52). Crayfish have 
been found to express serotonin and serotonin receptors within various tissues(53,54). Genetic 
studies concluded that 5-HT1A and 5-HT2 were conserved compared with Procambarus clarkii 
(southern swamp crayfish) and Panulirus interruptus (lobster) in structure and function (55). 
Direct injections of serotonin into the brains of crayfish induced an avoidance behavior and 
decreased movement when placed into a light-dark maze (56). This provides insight into how 5-
HT plays a role in the CNS of crayfish and produces anxiety like behaviors. However, within the 
peripheral nervous system the effects of serotonin are vastly different. Serotonin has been found 
to alter aggressive behaviors and cause changes in social ranking (57). This change is due to 
unidentified subtype receptors being found within the tail neural circuits that controls tail-flip 
escape behavior (58). Specifically, the Lateral Giant (LG) neurons receives input from 
mechanosensory of the abdomen (59). With the use of the pharmacological 5-HT neurotoxin 5,7-
Dihydroxytryptamine the LG neuron was shown to be directly modulated by 5-HT (60). The 
excitatory postsynaptic potential (EPSP) for the LG neuron has been shown to be inhibited by 
excessive serotonin in both monosynaptic(α) and di-synaptic(β) connections (61,62). Serotonin 
has also been shown to depolarize the LG neuron allowing for less resistance to distal dendrites 
(63). A study conducted using 5-HT1A  and 5-HT2  receptor agonists, 1-(3-chlorophenyl) 
piperazine dichloride (m-CPP Cl2) and α-methylserotonin meleate (α-CH3 5-HT maleate) 
respectively, concluded that social isolation, subordination and dominance played a key role in 
how the EPSP changes from serotonin. The specific receptor subtypes identified from the study 
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were 5-HT1 and 5-HT2  like receptors that act in inhibition and excitation, respectively, when 
serotonin is present (64). With the connection that tail flip behavior was associated with 5-HT, 
the next logical step examined if SSRIs could decrease the retreating muscular reflex from the 
LG nerve. Injections of 5-HT directly into equally sized crayfish increased their fighting 
durations and intensity favoring aggression. Preliminary studies using acute injects of fluoxetine 
(Prozac) indicated that SSRIs had negligible behavioral changes, but this was expected as with 
humans the same result have been found. Notable changes with SSRIs require extended 
treatment times (65). Additional studies with fluoxetine postulated that during elevated levels 
serotonin is taken up by the LG neuron and released during times of fights. This would account 
for the fact the various concentrations of 5-HT change fight characteristics but the use of acute 
SSRIs had little to no effect (66). However, acute use of fluoxetine was shown to increase the 
amplitude of the ESPS at the neuromuscular junction indicating an excitatory effect, while 
chronic use had no effect. This was postulated to be caused by changes made to glutamate 
neurotransmitter release, potentially causing reuptake inhibition as with serotonin (67). This 
would account for the fact that other naturally occurring anxiolytics have been shown to play a 
role in glutamate related neural activity. One such example is Hypericum perforatum from St 
John’s Wort(68). This would also account for the observed action of endocannabinoids on the 
crayfish neuromuscular junction. Initial use of a cannabinoid like pharmacological agent 
indicated a glutamatergic decrease in EPSP amplitude in crayfish at the NMJ (48), while this was 
later identified as CB1 receptors from immunofluorescence and microscopy (47). Further studies 
using CB1 receptor agonist found that the EPSP was decreased at the NMJ in crayfish (69). 
Currently, there no published studies that look at crayfish behavior with injections of 
endocannabinoids, including cannabidiol. Since CBD has been shown to act as an allosteric 
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inhibitor of CB1 receptors this could play a role in motility and was addressed in this study as a 
potential confounding variable for behavior analysis. Initial trials were conducted to measure the 
degree that CBD can alter movement.   
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Methods and Materials 
Animals 
Male and female intermolt (form I) crayfish, Faxonius propinquus, with fully intact 
appendages were socially and physically isolated in a flow-through holding tank. Crayfish will 
also be kept at a constant temperature (23C) and light:dark cycle (14hr:10hr) and crayfish were 
isolated for a minimum of one week prior to experimentation to reduce the effects of prior social 
experience for fight trial. Crayfish were size-matched within 90% for carapace length (from 
rostrum to beginning of abdomen) and weight to reduce size influences on fights (70). Each 
crayfish, regardless of treatment, were used only once during this study. Crayfish were marked 
with white correction fluid on the carapace for later identification during behavioral analysis for 
fights (Bergman lab). For hunger analysis crayfish were deprived of food for a minimum of two 
days prior to study. Crayfish used for the motility trials were not isolated or starved prior to 
injections.  
Drug Selection 
 To determine the effects of CBD on aggression, food seeking, and neural activity the use 
of Van Harreveld’s (VH) saline solution was employed as a vehicle control. The standard control 
was 5-HT. For all trials 5-HT was injected at a concentration of 5ug/g, a concentration sufficient 
to cause postural changes (71). The control (Van Harreveld’s solution) consisted of 12 g of 
NaCl, 0.4 g of KCl, 2 g of CaCl2, 0.5 g of MgCl2, 0.2 g of NaHCO3 per 1 L of H2O with a pH of 
7.4 (72). CBD trials for hunger were administered at a dose of 2.0 μg/g, 5 μg/g, and 10 μg/g. For 
fight analysis only 2.0 μg/g of CBD was injected, and 10 μg/g for motility studies. These 
concentration were chosen from previous rodent studies (42).    
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Drug administration and preparation 
 
  Crayfish weight was used to determine proper amount of drug required for each animal. 
Crayfish were then randomly assigned to an experimental group. Syringe injections were 
completed through the dorsal portion of the tail between abdomen plates into the cardiac sinus. A 
petroleum jelly (Vaseline) was used to help seal the wound and prevent leakage. Crayfish which 
weighted above 5g received injections of 1.0 ml while smaller crayfish received 0.5 ml injects. 
The compound concentration injected relative to the size remained the same. For the CBD 
injections, initial stock of 1.0mg/ml ampule suspended in methanol was dried over air until CBD 
globules remained. The CBD was reconstituted with VH Saline at a concentration of 0.2mg/ml 
by heating to 70 degrees Celsius while stirring with a magnetic stir bar.   
Behavior observations 
Aim 1: Aggressive interaction protocol 
 
For fight experiments, crayfish were tested in pairs consisting of animals that differed 
by no more than 10% in body weight and 10% in carapace length and were the same sex. After 
injection of solution the crayfish were placed in the separate compartments of the fight arena and 
allowed to acclimate for 15 min. The fight arena is made of Plexiglas (20 × 20 × 14 cm) and is 
divided into halves, separated by opaque retractable walls. The arena holds 10L of dechlorinated 
water (filled to a depth of 4 cm from the top of the tank). After acclimation, the divider was 
removed, allowing two crayfish to interact. An opaque curtain surrounds the fight tank to prevent 
external distractions. The interacting animals were video recorded for 15 to 30 minutes. After the 
fight the crayfish were returned to isolation tanks and not reused in future trials (Bergman lab).  
Aim 1: Fight Analysis 
 
All fights were digitally recorded from a camera positioned one meter above the test 
arena. For each encounter, recordings of the winners and losers of each fight was determined as 
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well as the temporal mechanics of the fight (Table 1). Temporal mechanics include time to 
different fight intensities and duration of the initial encounter. All interactions were analyzed by 
examining the behavior of both participants while each individual receives a unique ethogram 
value. In addition, the percent of time spent in interactions was analyzed.  
The identities of initiating and winning animals are to be recorded for each interaction. 
The crayfish that first engages an opponent with either a meral spread (Claws raised) or 
physically contact was deemed the initiator. The dominant crayfish is determined by the animal 
that pursues its opponent (i.e. the loser) as it retreats or tail-flips away, or if the two crayfish 
adopt body postures indicating dominance. Dominant crayfish tend to exhibit high body 
postures, extended tails and pointing or raised claws, whereas subordinate crayfish tend to 
exhibit lowered body position and tails curled under the body (70). Prior studies indicate that 5-
HT can induce an “aggressive posture" that resembles a meral spread – a common display of 
dominant animals (73). Yet Tierney and Mangiamele (2001) note that the aggressive meral 
spread posture could involve either an elevated or depressed posture, so when observing postural 
effects alone status roles will not necessarily be assigned.  
Table 1: Crayfish Ethogram Codes (Used to score fight intensity levels) 
Intensity 
Level Description 
-2 Tailflip away from opponent or fast retreat 
-1 Retreat by slowly backing away from opponent 
0 Visually ignore opponent with no response or threat display 
1 Approach without a threat display; claws raised 
2 Initial claw use by boxing, pushing and/or touching 
3 Active claw use by grabbing and/or holding opponent 
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Aim 2: Hunger and food-seeking 
 
 To determine the effects CBD has on food-seeking behavior and hunger, each pre-starved 
crayfish was injected with 2ug/g, 5 ug/g, 10ug/g CBD, VH saline control or 5ug/g 5-HT and 
placed into a small isolated tank approximately 10 inches by 10 inches and allowed five minutes 
to acclimate. The weight of a small portion of a tilapia filet was taken prior to being placed into 
the insolation tank. After 10 minutes, if the fila piece remained intact it was removed, dried, and 
weighted again. The difference in initial and final weights were used a percent indicator for how 
much was consumed. 
Aim 3: Motility 
 
 To assess the degree that CBD plays on the NMJ, crayfish were injected with saline 
control Van Harreveld’s solution or 10ug/g CBD and placed an isolation tank with opaque 
curtain to decrease external distractions. The animals were video recorded to observed total 
distance explored in the tank for the initial 12 minutes. The crayfish was then returned to 
isolation tanks and not reused for further trials.  
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Results 
Statistics 
 All statistical analysis was completed using SPSS 25 provided by Grand Valley State 
University. A significance level of 0.05 was used for hypothesis testing outcomes.  
Motility 
 The descriptive statistics for the motility trials can be found in Table 2. From this data 
Figure 1 displays the mean percent of time resting while Figure 2 is the mean percent of time 
moving. Table 3 displays the group statistics for number of samples based on compound. Note 
how the VH saline controls had a large standard deviation compared to the CBD. These results 
were analyses with a two-sample T-test of means(Table 4) which yielded no significant 
difference. A Mann-Whitney U Test was performed and no significance was found using a non-
parametric testing method as well.  
 
Table 2 Descriptive Statistics for Motility 
 
 Compound Statistic Std. Error 
Percent Time Resting Blank VH Saline Mean 50.5000 11.01741 
95% Confidence Interval for 
Mean 
Lower Bound 22.1788  
Upper Bound 78.8212  
5% Trimmed Mean 50.2037  
Median 48.5000  
Variance 728.300  
Std. Deviation 26.98703  
Minimum 20.67  
Maximum 85.67  
Range 65.00  
Interquartile Range 51.50  
Skewness .188 .845 
Kurtosis -2.258 1.741 
10 ug/mg CBD Mean 52.0202 3.35792 
Lower Bound 44.0799  
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95% Confidence Interval for 
Mean 
Upper Bound 59.9604 
 
5% Trimmed Mean 52.3743  
Median 52.8333  
Variance 90.205  
Std. Deviation 9.49763  
Minimum 31.67  
Maximum 66.00  
Range 34.33  
Interquartile Range 3.95  
Skewness -1.254 .752 
Kurtosis 3.948 1.481 
Percent Time Moving Blank VH Saline Mean 49.5000 11.01741 
95% Confidence Interval for 
Mean 
Lower Bound 21.1788  
Upper Bound 77.8212  
5% Trimmed Mean 49.7963  
Median 51.5000  
Variance 728.300  
Std. Deviation 26.98703  
Minimum 14.33  
Maximum 79.33  
Range 65.00  
Interquartile Range 51.50  
Skewness -.188 .845 
Kurtosis -2.258 1.741 
10 ug/mg CBD Mean 47.9798 3.35792 
95% Confidence Interval for 
Mean 
Lower Bound 40.0396  
Upper Bound 55.9201  
5% Trimmed Mean 47.6257  
Median 47.1667  
Variance 90.205  
Std. Deviation 9.49763  
Minimum 34.00  
Maximum 68.33  
Range 34.33  
Interquartile Range 3.95  
Skewness 1.254 .752 
Kurtosis 3.948 1.481 
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Figure 1 Mean Percent of Time Resting Based on Compound 
 
 
Figure 2 Mean Percent of Time Spent Moving Based on Compound 
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Table 3 Motility Statistics Summary 
 
 Compound N Mean Std. Deviation Std. Error Mean 
Percent Time Resting Blank VH Saline 6 50.5000 26.98703 11.01741 
10 ug/mg CBD 8 52.0202 9.49763 3.35792 
Percent Time Moving Blank VH Saline 6 49.5000 26.98703 11.01741 
10 ug/mg CBD 8 47.9798 9.49763 3.35792 
 
 
Table 4 Independent Samples Test For Percent Time Resting and Moving 
 
 
Levene's 
Test for 
Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. 
(2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Percent Time 
Resting 
Equal 
variances 
assumed 
17.580 .001 -
.149 
12 .884 -1.52016 10.19098 -
23.72440 
20.68408 
Equal 
variances 
not 
assumed 
  
-
.132 
5.935 .899 -1.52016 11.51777 -
29.77754 
26.73722 
Percent Time 
Moving 
Equal 
variances 
assumed 
17.580 .001 .149 12 .884 1.52016 10.19098 -
20.68408 
23.72440 
Equal 
variances 
not 
assumed 
  
.132 5.935 .899 1.52016 11.51777 -
26.73722 
29.77754 
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Fights 
 The descriptive statistics can be found in Table 5 for the two areas of interest for fight 
analysis. The values analyzed included the mean fight score by ethogram, and the percent of time 
spent fighting. Boxplots were generated for the mean fight scores based on compound (Figure 3) 
and the mean percent of time spent fighting by compound injected (Figure 4). Table 6 redisplays 
the descriptive statistics for the ANOVA analysis completed in Table 7. Significance was found 
with a pvalue of 0.004 for percent of time fighting being different between injection types. No 
significance was found for total fights in the first twelve minutes(additional area investigated) 
and mean fight ethogram score. Table 8 displays the post-hoc analysis which indicates that 
significance found for mean percent of time fighting was higher for both the CBD and 5HT when 
compared to Blank VH saline control injections. All other areas held no significance. A summary 
of the number of trials completed for analysis was generated(Table 9). Additional analysis was 
completed to examine how the effects of pair-wise matching by compound injected might 
change the means. Table 10 includes the number of samples used while Table 11 details the 
descriptive statistics for the pair-wise analysis. Boxplots for Mean Fight Score(Figure 5) showed 
less variance as compared to the Mean Percent Time Fighting(Figure 6) based on the compound 
pairing type specifically for the CBD-5-HT pairings. ANOVA analysis was completed (Table 
12). Significance was found that Mean Percent of Time Fighting was not the same for all groups 
analyzed. Post-Hoc analysis in Table 13 shows that the CBD-5HT injections pairs had 
significantly longer fight times compared to Blank-Blank, Blank-CBD, and Blank-5HT injection 
pairings. Due to the low number of subjects a non-parametric test was conducted and yielded 
similar results to the ANOVA analysis. Figure 7 displays the hypothesis test summary for pair-
wise analysis of Mean Fight Score and Mean Percent of Time Fighting. Significance was found 
for the Mean Percent of Time Fighting but not for the Mean Fight Scores by group. Boxplot 
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summary and table of counts for the Kruskal-Wallis non-parametric testing can be found in 
Figure 8. A table of adjusted significance is displayed in Figure 9. Statistical significance was 
found that the Blank-Blank compared to CBD-5-HT pairing fights for Mean Percent of Time 
Fighting were not the same. Finally Figure 10 displays the non-parametric box plots and 
summary for fight analysis based on ethogram which yielded no statistical significance. The 
comparison of blank/saline-blank/saline to CBD-5HT yielded statistically different distribution 
of mean percent time spent fighting. This correlates with the results found from the parametric 
testing.  
 
 
Table 5 Descriptive Statistics for Paired Fight Analysis for Individual Injection Type  
 
 Compound Statistic Std. Error 
Mean Fight Score Blank Mean .656685 .0897042 
95% Confidence Interval for 
Mean 
Lower Bound .462891  
Upper Bound .850479  
5% Trimmed Mean .669979  
Median .721154  
Variance .113  
Std. Deviation .3356425  
Minimum .0000  
Maximum 1.0741  
Range 1.0741  
Interquartile Range .3214  
Skewness -1.016 .597 
Kurtosis .474 1.154 
CBD Mean .761996 .1101632 
95% Confidence Interval for 
Mean 
Lower Bound .501502  
Upper Bound 1.022491  
5% Trimmed Mean .794031  
Median .862534  
Variance .097  
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Std. Deviation .3115887  
Minimum .0000  
Maximum .9474  
Range .9474  
Interquartile Range .1054  
Skewness -2.697 .752 
Kurtosis 7.442 1.481 
5HT Mean .720250 .0998248 
95% Confidence Interval for 
Mean 
Lower Bound .484202  
Upper Bound .956298  
5% Trimmed Mean .718091  
Median .723636  
Variance .080  
Std. Deviation .2823471  
Minimum .2222  
Maximum 1.2571  
Range 1.0349  
Interquartile Range .1613  
Skewness .256 .752 
Kurtosis 2.914 1.481 
Percent Time Fighting Blank Mean 16.381926 2.5435482 
95% Confidence Interval for 
Mean 
Lower Bound 10.886924  
Upper Bound 21.876927  
5% Trimmed Mean 16.187434  
Median 17.049001  
Variance 90.575  
Std. Deviation 9.5170859  
Minimum 2.0000  
Maximum 34.2647  
Range 32.2647  
Interquartile Range 13.3939  
Skewness .394 .597 
Kurtosis -.394 1.154 
CBD Mean 38.122512 7.6897197 
95% Confidence Interval for 
Mean 
Lower Bound 19.939214  
Upper Bound 56.305809  
5% Trimmed Mean 38.120920  
Median 33.529412  
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Variance 473.054  
Std. Deviation 21.7498117  
Minimum 8.6667  
Maximum 67.6070  
Range 58.9403  
Interquartile Range 43.3895  
Skewness .143 .752 
Kurtosis -1.184 1.481 
5HT Mean 39.327267 7.3418015 
95% Confidence Interval for 
Mean 
Lower Bound 21.966665  
Upper Bound 56.687869  
5% Trimmed Mean 39.494039  
Median 35.368127  
Variance 431.216  
Std. Deviation 20.7657506  
Minimum 8.0943  
Maximum 67.5584  
Range 59.4641  
Interquartile Range 38.1281  
Skewness .100 .752 
Kurtosis -.885 1.481 
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Figure 3 Mean Fight Score by Ethogram based on Compound Used 
 
 
 
Figure 4 Mean Percent of Time Fighting based on Compound Used 
 
 
Table 6 Descriptive For Fight Analysis based on Compound 
 
 N Mean 
Std. 
Deviation Std. Error 
95% Confidence Interval 
for Mean Minimum 
Maximu
m 
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Lower 
Bound 
Upper 
Bound 
Percent Time Fighting Blank 1
4 
16.3819
26 
9.517085
9 
2.543548
2 
10.88692
4 
21.876927 2.0000 34.2647 
CBD 8 38.1225
12 
21.74981
17 
7.689719
7 
19.93921
4 
56.305809 8.6667 67.6070 
5HT 8 39.3272
67 
20.76575
06 
7.341801
5 
21.96666
5 
56.687869 8.0943 67.5584 
Total 3
0 
28.2981
73 
19.68772
99 
3.594471
3 
20.94665
4 
35.649692 2.0000 67.6070 
Total Fights In First 
12 mins 
Blank 1
4 
4.00 2.287 .611 2.68 5.32 1 8 
CBD 8 3.50 1.414 .500 2.32 4.68 2 6 
5HT 8 4.88 2.588 .915 2.71 7.04 2 9 
Total 3
0 
4.10 2.171 .396 3.29 4.91 1 9 
Mean Fight Score Blank 1
4 
.656685 .3356425 .0897042 .462891 .850479 .0000 1.0741 
CBD 8 .761996 .3115887 .1101632 .501502 1.022491 .0000 .9474 
5HT 8 .720250 .2823471 .0998248 .484202 .956298 .2222 1.2571 
Total 3
0 
.701719 .3086335 .0563485 .586473 .816964 .0000 1.2571 
 
Table 7 ANOVA Significance for Fight Analysis based on Compound 
 
 
Sum of 
Squares df Mean Square F Sig. 
Percent Time Fighting Between Groups 3733.226 2 1866.613 6.713 .004 
Within Groups 7507.369 27 278.051   
Total 11240.595 29    
Total Fights In First 
12mins 
Between Groups 7.825 2 3.913 .820 .451 
Within Groups 128.875 27 4.773   
Total 136.700 29    
Mean Fight Score Between Groups .060 2 .030 .301 .743 
Within Groups 2.702 27 .100   
Total 2.762 29    
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Table 8 Multiple Comparisons for Fight Analysis based on Compound 
 
Tukey HSD   
Dependent Variable 
(I) 
CompoundN
umeric 
(J) 
Compoun
dNumeric 
Mean 
Difference (I-
J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound 
Upper 
Bound 
Percent Time 
Fighting 
Blank CBD -21.7405859* 7.3903384 .018 -40.064322 -
3.416850 
5HT -22.9453412* 7.3903384 .012 -41.269077 -
4.621605 
CBD Blank 21.7405859* 7.3903384 .018 3.416850 40.06432
2 
5HT -1.2047553 8.3374262 .989 -21.876717 19.46720
7 
5HT Blank 22.9453412* 7.3903384 .012 4.621605 41.26907
7 
CBD 1.2047553 8.3374262 .989 -19.467207 21.87671
7 
Total Fights In First 
12 mins 
Blank CBD .500 .968 .864 -1.90 2.90 
5HT -.875 .968 .643 -3.28 1.53 
CBD Blank -.500 .968 .864 -2.90 1.90 
5HT -1.375 1.092 .430 -4.08 1.33 
5HT Blank .875 .968 .643 -1.53 3.28 
CBD 1.375 1.092 .430 -1.33 4.08 
Mean Fight Score Blank CBD -.1053115 .1402095 .736 -.452949 .242326 
5HT -.0635653 .1402095 .893 -.411203 .284073 
CBD Blank .1053115 .1402095 .736 -.242326 .452949 
5HT .0417462 .1581776 .962 -.350442 .433935 
5HT Blank .0635653 .1402095 .893 -.284073 .411203 
CBD -.0417462 .1581776 .962 -.433935 .350442 
*. The mean difference is significant at the 0.05 level. 
 
 
 
 
 
 
 
  
37 
 
Table 9 Case Processing Summary for Fight Analysis based on Compound Used 
 
 
Compound 
Cases 
 
Valid Missing Total 
 
N Percent N Percent N Percent 
Mean Fight Score Blank 14 100.0% 0 0.0% 14 100.0% 
CBD 8 100.0% 0 0.0% 8 100.0% 
5HT 8 100.0% 0 0.0% 8 100.0% 
Percent Time Fighting Blank 14 100.0% 0 0.0% 14 100.0% 
CBD 8 100.0% 0 0.0% 8 100.0% 
5HT 8 100.0% 0 0.0% 8 100.0% 
 
Table 10 Case Processing Summary for Fight Analysis when Examined by Fight 
Compound Pair Match Type 
 
 
FightBasedOnPairing 
Cases 
 
Valid Missing Total 
 
N Percent N Percent N Percent 
Mean Fight Score Blank-Blank 8 100.0% 0 0.0% 8 100.0% 
Blank-CBD 6 100.0% 0 0.0% 6 100.0% 
Blank-5HT 6 100.0% 0 0.0% 6 100.0% 
CBD-5HT 10 100.0% 0 0.0% 10 100.0% 
Percent Time 
Fighting 
Blank-Blank 8 100.0% 0 0.0% 8 100.0% 
Blank-CBD 6 100.0% 0 0.0% 6 100.0% 
Blank-5HT 6 100.0% 0 0.0% 6 100.0% 
CBD-5HT 10 100.0% 0 0.0% 10 100.0% 
 
Table 11 Descriptive Statistics for Fight Analysis by Compound Pair Match Type 
 
 FightBasedOnPairing Statistic Std. Error 
Mean Fight Score Blank-Blank Mean .821476 .0825685 
95% Confidence Interval for 
Mean 
Lower Bound .626232  
Upper Bound 1.016719  
5% Trimmed Mean .834561  
Median .836120  
Variance .055  
Std. Deviation .2335389  
Minimum .3333  
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Maximum 1.0741  
Range .7407  
Interquartile Range .2775  
Skewness -1.288 .752 
Kurtosis 2.503 1.481 
Blank-CBD Mean .663156 .1385670 
95% Confidence Interval for 
Mean 
Lower Bound .306958  
Upper Bound 1.019354  
5% Trimmed Mean .685914  
Median .769231  
Variance .115  
Std. Deviation .3394186  
Minimum .0000  
Maximum .9167  
Range .9167  
Interquartile Range .3720  
Skewness -2.009 .845 
Kurtosis 4.302 1.741 
Blank-5HT Mean .675463 .1651737 
95% Confidence Interval for 
Mean 
Lower Bound .250871  
Upper Bound 1.100056  
5% Trimmed Mean .680673  
Median .686217  
Variance .164  
Std. Deviation .4045914  
Minimum .0000  
Maximum 1.2571  
Range 1.2571  
Interquartile Range .4552  
Skewness -.495 .845 
Kurtosis 2.187 1.741 
CBD-5HT Mean .644804 .0957962 
95% Confidence Interval for 
Mean 
Lower Bound .428098  
Upper Bound .861510  
5% Trimmed Mean .663817  
Median .726667  
Variance .092  
Std. Deviation .3029340  
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Minimum .0000  
Maximum .9474  
Range .9474  
Interquartile Range .3610  
Skewness -1.442 .687 
Kurtosis 1.334 1.334 
Percent Time Fighting Blank-Blank Mean 13.547899 1.9583838 
95% Confidence Interval for 
Mean 
Lower Bound 8.917057  
Upper Bound 18.178741  
5% Trimmed Mean 13.714009  
Median 16.745061  
Variance 30.682  
Std. Deviation 5.5391459  
Minimum 5.7385  
Maximum 18.3673  
Range 12.6289  
Interquartile Range 10.6705  
Skewness -.637 .752 
Kurtosis -2.042 1.481 
Blank-CBD Mean 23.910131 5.9498709 
95% Confidence Interval for 
Mean 
Lower Bound 8.615501  
Upper Bound 39.204761  
5% Trimmed Mean 24.552106  
Median 32.352941  
Variance 212.406  
Std. Deviation 14.5741478  
Minimum 2.0000  
Maximum 34.2647  
Range 32.2647  
Interquartile Range 26.9338  
Skewness -1.040 .845 
Kurtosis -1.340 1.741 
Blank-5HT Mean 18.869403 3.6548650 
95% Confidence Interval for 
Mean 
Lower Bound 9.474274  
Upper Bound 28.264533  
5% Trimmed Mean 18.820056  
Median 20.542636  
Variance 80.148  
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Std. Deviation 8.9525543  
Minimum 8.0943  
Maximum 30.5328  
Range 22.4385  
Interquartile Range 17.8279  
Skewness -.213 .845 
Kurtosis -1.407 1.741 
CBD-5HT Mean 48.388479 5.9041803 
95% Confidence Interval for 
Mean 
Lower Bound 35.032295  
Upper Bound 61.744663  
5% Trimmed Mean 49.232394  
Median 50.939457  
Variance 348.593  
Std. Deviation 18.6706576  
Minimum 13.9795  
Maximum 67.6070  
Range 53.6275  
Interquartile Range 31.7335  
Skewness -.557 .687 
Kurtosis -.783 1.334 
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Figure 5 Mean Fight Score by Ethogram Based on Compound Pair Match Type 
 
 
 
 
Figure 6 Mean Percent Time Fighting based on Compound Pair Match Type 
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Table 12 ANOVA Results for Fights based on Compound Pair Match Type 
  
 
Sum of 
Squares df Mean Square F Sig. 
Mean Fight Score Between Groups .160 3 .053 .533 .663 
Within Groups 2.602 26 .100   
Total 2.762 29    
Percent Time Fighting Between Groups 6425.708 3 2141.903 11.566 .000 
Within Groups 4814.886 26 185.188   
Total 11240.595 29    
 
Table 13 Multiple Comparisons for Fights based on Compound Pair Match Type 
 
Tukey HSD   
Dependent Variable 
(I) 
FightBased
OnPairing 
(J) 
FightBased
OnPairing 
Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Mean Fight Score Blank-
Blank 
Blank-CBD .1583193 .1708547 .791 -.310390 .627029 
Blank-5HT .1460124 .1708547 .828 -.322697 .614722 
CBD-5HT .1766719 .1500634 .646 -.235000 .588344 
Blank-CBD Blank-Blank -.1583193 .1708547 .791 -.627029 .310390 
Blank-5HT -.0123070 .1826514 1.000 -.513378 .488764 
CBD-5HT .0183526 .1633684 .999 -.429819 .466524 
Blank-5HT Blank-Blank -.1460124 .1708547 .828 -.614722 .322697 
Blank-CBD .0123070 .1826514 1.000 -.488764 .513378 
CBD-5HT .0306595 .1633684 .998 -.417512 .478831 
CBD-5HT Blank-Blank -.1766719 .1500634 .646 -.588344 .235000 
Blank-CBD -.0183526 .1633684 .999 -.466524 .429819 
Blank-5HT -.0306595 .1633684 .998 -.478831 .417512 
Percent Time Fighting Blank-
Blank 
Blank-CBD -10.3622318 7.3493636 .505 -30.523887 9.799423 
Blank-5HT -5.3215042 7.3493636 .887 -25.483159 14.840151 
CBD-5HT -34.8405803* 6.4550200 .000 -52.548765 -17.132396 
Blank-CBD Blank-Blank 10.3622318 7.3493636 .505 -9.799423 30.523887 
Blank-5HT 5.0407276 7.8568002 .918 -16.512988 26.594444 
CBD-5HT -24.4783485* 7.0273357 .009 -43.756578 -5.200119 
Blank-5HT Blank-Blank 5.3215042 7.3493636 .887 -14.840151 25.483159 
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Blank-CBD -5.0407276 7.8568002 .918 -26.594444 16.512988 
CBD-5HT -29.5190761* 7.0273357 .001 -48.797306 -10.240846 
CBD-5HT Blank-Blank 34.8405803* 6.4550200 .000 17.132396 52.548765 
Blank-CBD 24.4783485* 7.0273357 .009 5.200119 43.756578 
Blank-5HT 29.5190761* 7.0273357 .001 10.240846 48.797306 
*. The mean difference is significant at the 0.05 level. 
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Figure 7 Non-parametric Analysis of Time Spent Fighting By Pair Match Type 
 
 
Figure 8 Non-parametric Boxplots for Pair-based Time Spent Fighting by Pair Match Type 
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Figure 9 Pairwise Comparisons of Mean Percent of Time Fighting and Hypothesis Table 
for Non-parametric Testing by Pair Match Type 
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Figure 10 Non-Parametric Box Plots and Summary for Fight Analysis based on Ethogram 
Score for Pair Match Type 
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Hunger 
 The number analyzed for each compound type is summarized in table 14. A table of 
descriptive statistics(Table 15) for mean percent of food consumed based on the compound 
injected and concentration was generated. A boxplots was generated for the mean percent of 
food consumed based on compound and concentration(Figure 11). ANOVA analysis was 
completed (Table 16) and yielded no statistical significance for variance in percent of food 
consumed. The results for statistical comparison based on compound were used to create a 
means plot(Figure 12). No significance was found between groups for percent of food consumed.  
 
Table 14 Case Processing Summary for Percent Food Consumed by Compound and 
Concentration 
 
 
Compound 
Cases 
 
Valid Missing Total 
 
N Percent N Percent N Percent 
Percent Food Consumed Blank 16 100.0% 0 0.0% 16 100.0% 
CBD 2ug/mg 12 100.0% 0 0.0% 12 100.0% 
CBD 5ug/mg 16 100.0% 0 0.0% 16 100.0% 
5HT 5ug/mg 16 100.0% 0 0.0% 16 100.0% 
CBD 10ug/mg 16 100.0% 0 0.0% 16 100.0% 
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Table 15 Descriptive Statistics for Mean Percent Food Consumed by Compound and 
Concentration 
 
 Compound Statistic Std. Error 
Percent Food 
Consumed 
Blank Mean .0406 .02046 
95% Confidence Interval for Mean Lower Bound -.0030  
Upper Bound .0842  
5% Trimmed Mean .0318  
Median .0000  
Variance .007  
Std. Deviation .08185  
Minimum .00  
Maximum .24  
Range .24  
Interquartile Range .04  
Skewness 2.011 .564 
Kurtosis 2.809 1.091 
CBD 2ug/mg Mean .0200 .00870 
95% Confidence Interval for Mean Lower Bound .0008  
Upper Bound .0392  
5% Trimmed Mean .0178  
Median .0000  
Variance .001  
Std. Deviation .03015  
Minimum .00  
Maximum .08  
Range .08  
Interquartile Range .05  
Skewness 1.242 .637 
Kurtosis .001 1.232 
CBD 5ug/mg Mean .0219 .01152 
95% Confidence Interval for Mean Lower Bound -.0027  
Upper Bound .0464  
5% Trimmed Mean .0143  
Median .0000  
Variance .002  
Std. Deviation .04608  
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Minimum .00  
Maximum .18  
Range .18  
Interquartile Range .02  
Skewness 3.064 .564 
Kurtosis 10.219 1.091 
5HT 5ug/mg Mean .0163 .00826 
95% Confidence Interval for Mean Lower Bound -.0014  
Upper Bound .0339  
5% Trimmed Mean .0114  
Median .0000  
Variance .001  
Std. Deviation .03304  
Minimum .00  
Maximum .12  
Range .12  
Interquartile Range .02  
Skewness 2.596 .564 
Kurtosis 6.734 1.091 
CBD 10ug/mg Mean .0050 .00438 
95% Confidence Interval for Mean Lower Bound -.0043  
Upper Bound .0143  
5% Trimmed Mean .0017  
Median .0000  
Variance .000  
Std. Deviation .01751  
Minimum .00  
Maximum .07  
Range .07  
Interquartile Range .00  
Skewness 3.873 .564 
Kurtosis 15.213 1.091 
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Figure 11 Mean Percent Food Consumed base on Compound and Concentration Injected 
 
 
 
 
Table 16 Multiple Comparisons For Mean Percent of Food Consumed based on Compound 
Used 
ANOVA 
PercentFoodConsumed   
 Sum of Squares df Mean Square F Sig. 
Between Groups .011 4 .003 1.156 .337 
Within Groups .163 71 .002   
Total .174 75    
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Figure 12 Means Plot for Percent Food Consumed based on Compound and Concentration 
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Discussion 
Motility 
 The purpose of examining motility was to determine if injections of CBD would 
influence the outcomes from fights by hindering movement. Part of the complex social 
interaction during a fight involves both postural changes and raising the claws into a meral 
spread (73). Immunofluorescence tagging of CB1 receptors in crayfish have been identified via 
microscopy (47). In addition, EPSP amplitudes were decreased at the NMJ after cannabidiol-like 
agent was used, suggesting that CBD would down regulate AP frequency at the muscular 
junction (67,69). Our research demonstrated a general decrease in movement after CBD 
injections compared to VH saline controls (i.e. blanks). However, no statistical significance was 
found overall indicating that movement was not inhibited or promoted from injections of CBD 
when compared against VH saline controls. The number of trials was relatively small though, 
with only 6 VH saline injections and 8 CBD injections completed. A larger sample may help to 
indicate overall reductions in motility. In addition, only one high concentrated dose of 10ug/g 
was administered due to time constraints brought on by COVID-19. Future trials could be 
completed using a range of doses. Perhaps a better indicator of influence of the NMJ would be 
trials based on treadmill activity or food seeking behavior where more time would be spent 
purposefully in movement rather than passively exploring. For the purpose of this project, the 
goal from motility analysis was to determine if CBD interacted with the NMJ enough to 
influence the interaction for dominance with competing crayfish. Based on the above results, the 
change in movement was not significant enough to inhibit or influence the outcome of a fight at 
the doses administered. 
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Fights 
 The two main ways fight interactions were analyzed involved a mean behavioral 
ethogram score of aggression (Table 1), and mean percent of time spent fighting. Serotonin has 
been shown to directly influence tail-flip response in crayfish (58). The decreased EPSP at the 
Lateral Giant (LG) neuron via increased synaptic 5-HT directly influenced behavior (61,62). 
CBD has been known to act on 5-HT receptors in mammalian models (74). It was postulated that 
if CBD interacted with the LG neuron of the tail tissue influencing fights that the measured value 
for the ethogram score would increase. However, this was not observed when compared against 
all other groups. Video analysis of fights included ethogram ranking, tail-flip counts, percent of 
time interacting in a fight, total number of interactions during the initial 12 minutes of recording, 
and if a crayfish died during the fight. Only two areas, mean ethogram rank and mean percent of 
time fighting based on pairs, were noted for any significance of frequency and were pursued for 
statistical significance. No significance was observed for the ethogram ranking using parametric 
and non-parametric tests. However, the analysis of mean percent time fighting based on injection 
pairing types yielded significance for both parametric and non-parametric tests. Specifically VH 
saline control-control pairs compared to CBD-5-HT pairs indicated that the means were 
statistically different with a p-value of 0.001 using Kruskal-Wallis analysis. Blank-Saline control 
pairs had a mean of 13.54% compared to 48.39% for CBD-5HT pairs. This influence is 
postulated to be from CBD binding to the 5-HT1 receptors on the LG neuron acting as a agonist, 
thus inhibiting the EPSP for tail-flip retreat behavior and increasing aggressive posturing and 
meral spread. The CBD could act two fold by both activating the 5-HT1A receptors as well as 
increasing synaptic serotonin that would otherwise bind to the respective receptors. The 
significance found for CBD influencing fights was concluded with a concentration of 2 ug/g as 
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compared to the 5ug/g 5-HT. If the U-shaped curved observed with most pharmacological agents 
is applied to CBD than the optimal concentration could be different from what was used for 
testing. This means that the significant difference observed could be amplified with the proper 
dosage. General observation of the fights indicated that 5-HT produced aggressive fight 
behaviors such as curved tail postures, meral spread, and rapid pursuit of opponents. CBD 
produced a passive, responsive behavior to pursuers where fights were not sought out as quickly 
as with 5-HT. A meral spread (raised claws) and curved posture were still produced when 
opponents approached CBD crayfish. However, once engaged in a fight CBD crayfish appeared 
to retreat less frequently than VH saline injected crayfish. This would explain the relative 
similarity in ethogram ranking and the increase in percent of time spent engaged in combat. 
These observations were anecdotal and therefore not accurately measured behaviors and the 
validity remains unknown. Review of raw data indicated that the number of ethogram rankings 
of 1 (pursuing opponent) were scattered and no clear pattern emerged using this method. 
Additional video analysis could be conducted with a reconstructed ethogram to observe only 
pursuit behavior. The fights were completed with a low number of trials as three of the four main 
injection types were conducted with only 6 paired fights. Additional pairings would increase the 
power of the analysis. These pairings could include CBD-CBD and 5-HT-5-HT compound 
matching to better assess the fight outcomes. For this study, the significance found for mean 
percent of time fighting builds on previous postulations that CBD would influence the tail-flip 
response to retreat from fights and indicates a relationship between cannabinoids and crayfish 
behavior. 
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 Hunger 
 Food seeking behavior was addressed extensively with a range of CBD concentrations. 
The purpose was to explore the possibility that cannabinoids could influence various receptors 
throughout the nervous system of crayfish, including the 5-HT subtypes found throughout the 
eye-stalks and central nervous system (55). These receptors line the digestive system of crayfish 
as well and could result in alterations in hunger if stimulated. However, after extensive analysis 
at multiple concentrations statistical significance was not found for CBD injections changing the 
amount of food consumed as compared to blank-saline controls or 5-HT injections. This may be 
due to the injury incurred during the injection process, as all animals exhibited the same lack of 
hunger despite being deprived of food prior to testing. To properly address the potential that 
injury influences the drive for food, alternative drug delivery methods could be employed, such 
as the placement of a capillary tube and/or using an injection pump after the injection site heals. 
In addition, a Y-maze could be utilized to further address a drive to pursue food over an extended 
period of time. For the purpose of this analysis, no observed behavioral changes occurred after 
injections of CBD to influence amount of food consumed. 
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Conclusion 
 To date, no trials have been published that involved cannabinoids and behavior analysis 
of crayfish. This project is the first step towards understanding how the simpler nervous system 
of crayfish utilizes cannabidiol with serotonin receptors. While no significance was found for 
CBD influencing motility and hunger, it was determined that there is a significant difference in 
mean time spent fighting when paired. This significance is postulated to be from activation of 5-
HT1A receptors. These receptors in humans are influenced by SSRIs to treat a variety of mental 
disorders such as anxiety and depression. SSRIs come with extensive side effects and that can 
partially decrease the quality of life and alter behaviors. The side effects from CBD are minimal 
when compared to SSRIs. However the effects of CBD, specifically in simple neurological 
models, has not been well studied. Yet, cannabis has gained wide-legalization across the US 
resulting in an increase in consumption of cannabinoids such as CBD. Further studies in crayfish 
and elsewhere should be completed to support the proper uses and dangers of cannabidiol within 
an unregulated market.  
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